Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease

American Journal of Cardiology

Volumn 103, Issue 3 SUPPL., 2009, Pages 11A-19A

  Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; METOPROLOL; NAPROXEN; PACLITAXEL; PLACEBO; PRASUGREL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG COST; DRUG ELUTING STENT; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SURGICAL MORTALITY; UNSPECIFIED SIDE EFFECT;

EID: 58249133166     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.11.018     Document Type: Article

References (35)

1. Meadows T.A., and Bhatt D.L. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100 (2007) 1261-1275
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Bhatt D.L. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 43 (2004) 1127-1129
4. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., Goto S., Liau C.S., Richard A.J., Röther J., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
5. ASCEND. ASCEND (A Study of Cardiovascular Events in Diabetes) Trial Web Site. Last update: April 15, 2008. http://www.ctsu.ox.ac.uk/ascend/ Accessed November 27, 2008
6. Savi P., and Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183
7. Bhatt D.L., Bertrand M.E., Berger P.B., L'Allier P.L., Moussa I., Moses J.W., Dangas G., Taniuchi M., Lasala J.M., Holmes D.R., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39 (2002) 9-14
8. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
10. Ringleb P.A., Bhatt D.L., Hirsch A.T., Topol E.J., and Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35 (2004) 528-532
11. Bhatt D.L., Marso S.P., Hirsch A.T., Ringleb P.A., Hacke W., and Topol E.J. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90 (2002) 625-628
12. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., and Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35 (2000) 922-928
13. Bertrand M.E., Legrand V., Boland J., Fleck E., Bonnier J., Emmanuelson H., Vrolix M., Missault L., Chierchia S., Casaccia M., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98 (1998) 1597-1603
14. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
15. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A., Pieper M., Wesseling T., and Sagnard L. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 (1998) 2126-2132
16. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
17. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
18. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J., and CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
19. Waksman R., Ajani A.E., Pinnow E., Cheneau E., Leborgne L., Dieble R., Bui A.B., Satler L.F., Pichard A.D., Kent K.K., et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106 (2002) 776-778
20. Sabatine M.S., Cannon C.P., Gibson C.M., López-Sendón J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
21. Sabatine M.S., Cannon C.P., Gibson C.M., López-Sendón J.L., Montalescot G., Theroux P., Lewis B.S., Murphy S.A., McCabe C.H., Braunwald E., et al., CLARITY-TIMI 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
22. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., Liu L.S., and COMMIT collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
23. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
24. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
25. Curfman G.D., Morrissey S., Jarcho J.A., and Drazen J.M. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med 356 (2007) 1059-1060
26. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
27. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., and Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 (2006) 1260-1264
28. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
29. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
30. Bavry A.A., and Bhatt D.L. Drug-eluting stents: dual antiplatelet therapy for every survivor?. Circulation 116 (2007) 696-699
31. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neill W.W., Schaff H.V., Whitlow P.L., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) e1-e121
32. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
33. Han Y., Zang H., Li Y., Wang S., Jing Q., Ma Y., Wang D., and Wang Z. Efficacy of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention. [abstract 114]. Am J Cardiol 100 (2007) 34L
34. Han Y., Xu K., Li Y., Wang S., Jing Q., Ma Y., Wang Z., and Wang D. High clopidogrel maintaining dosage improves long-term clinical outcomes in patients with acute coronary syndrome undergoing drug eluting stent implantation. [abstract 80]. Am J Cardiol 100 (2007) 39L
35. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015